Triplex is under clinical development by Helocyte Biosciences and currently in Phase II for Myeloproliferative Disorders. According to GlobalData, Phase II drugs for Myeloproliferative Disorders have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Triplex’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Triplex is under development for the treatment of Cytomegalovirus (HHV-5) infections, CMV associated HIV, liver transplant, kidney transplant, cytomegalovirus infections associated with stem cell transplantation in pediatric patients, Hodgkin/Non-Hodgkin lymphoma, myelodysplastic syndrome, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, myelofibrosis, b-cell non-Hodgkin lymphoma, diffuse large b-cell lymphoma, mantle cell lymphoma and multiple myeloma. The vaccine candidate consists of inactivated, modified vaccinia ankara (MVA) viral vector encoding three herpesvirus cytomegalovirus (CMV) tumor-associated antigens (TAAs), including UL83 (pp65), UL123 (IE1) and UL122 (IE2). It is administered through intramuscular route. It was also under development for the treatment of glioblastoma multiforme and hematological tumors.
Helocyte Biosciences overview
Helocyte is a clinical-stage biopharmaceutical company developing novel immunotherapies for the prevention and treatment of cancer. The company is headquartered in New York City, New York, the US
For a complete picture of Triplex’s drug-specific PTSR and LoA scores, buy the report here.